MIT Researchers Develop Self-Implanting Nanotech Brain Devices
MIT Media Lab researchers have created subcellular‑sized wireless bioelectronic devices, termed “circulatronics,” that hitch a ride on monocytes to traverse the bloodstream, cross the blood‑brain barrier, and autonomously implant in inflamed brain tissue. In mouse studies the implants self‑positioned, were powered wirelessly via external electromagnetic fields, and delivered localized electrical stimulation using near‑infrared light. The platform could replace invasive neurostimulation for conditions such as Alzheimer’s, glioblastoma and chronic pain. A spin‑out, Cahira Technologies, aims for first‑in‑human trials within three years, though long‑term safety and retrieval remain unresolved.
New Research Findings Challenge Old Beliefs About Myelin Repair in MS
Researchers using advanced imaging in mice discovered that oligodendrocyte precursor cells continuously differentiate into mature oligodendrocytes across the brain and spinal cord, regardless of myelin injury. This overturns the long‑standing belief that these cells only mature in response to damage....
Champion Insights Opens Nationwide Enrolment to Study ALS Risk in High-Performance Groups
Champion Insights has launched a nationwide enrollment to recruit up to 500 elite athletes, military veterans and first responders for a study investigating their elevated risk of amyotrophic lateral sclerosis (ALS). The remote study will collect blood samples and online...
Cure Parkinson’s Expands Its Research Committee and Welcomes New Interns
Cure Parkinson’s has expanded its Research Committee by adding eight new members from leading UK and European institutions, spanning neurology, bioinformatics, pharmacology and more. The charity also welcomed three early‑career researchers as interns, extending the programme beyond the UK to...
Five-Year Data Show Sustained Benefits with Briumvi in Relapsing MS
Long‑term data from the Phase 3 ULTIMATE I and II trials show that continuous treatment with Briumvi (ublituximab) provides sustained clinical benefits for relapsing multiple sclerosis over five years. More than 80 % of patients who started Briumvi remained free of relapses and...